XOMA Corporation (NASDAQ:XOMA)
Industry: Healthcare

OFF LIST - 2097 consecutive market days: OFF LIST as of 02/06/2008 Through 11/14/2016

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Current Quote*
Last: $24.650
Change: 0.010
Book: $8.218
Volume: 14,321

As Of: 11/14 12:58 ET
*Quotes delayed by 20min.

Graphs for XOMA


3 Month Graph


6 Month Graph


1 Year Graph